Clinical context

In retinal disease, an anatomical response on OCT does not always translate directly into functional improvement. Retinal thickness and fluid should therefore be considered alongside visual acuity, disease duration, outer retinal integrity, injection burden and durability. For chronic disease, it is especially important to know whether benefit persists beyond a short follow-up period and what treatment burden is required.

What was studied

The study compared volumetric intraretinal and subretinal fluid measures with conventional central retinal thickness.

How the evidence was produced

A cohort study describes how outcomes are associated with an exposure or treatment in an observed clinical population. This design is useful for routine practice, uncommon events and longer follow-up, but it remains vulnerable to confounding by indication, baseline risk differences and missing data. An association should not automatically be interpreted as a causal effect.

Key result Six-millimetre fluid volumes explained more variation in visual acuity, particularly in previously treated eyes.

How to interpret the result

Automated segmentation may provide a richer activity biomarker than one central-thickness value.

The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.

Clinical applicability

The evidence can help frame the expected balance of benefit, risk and visit burden, but it does not establish a universal regimen. Applicability depends on baseline vision, morphological subtype, previous therapy, retreatment rules and rescue treatment. Differences in these details may materially change the effect seen in routine practice.

Limitations

Associations were moderate, and observational data do not prove better decisions or outcomes.

Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.

What to verify in the source

In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.